Conaway Samuel 4

What Happened
Samuel Conaway, a member of Fractyl Health's board of directors, received a derivative award on 2026-06-10: an option covering 22,500 shares (reported at $0.00, no cash paid at grant). The filing characterizes this as an award under the company's non-employee director compensation policy rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-11 (filed timely).
• Transaction type/code: Award/Grant (A); derivative instrument (stock option) covering 22,500 shares.
• Reported price/value: $0.00 per share at grant (no cash paid on grant; total reported consideration $0).
• Vesting: vests and becomes exercisable in a single installment on the earlier of (i) the next annual shareholders' meeting or (ii) the first anniversary of the grant, contingent on continued service as a non-employee director.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: Award granted pursuant to the issuer’s non-employee director compensation policy.

Context
This is a routine director compensation award (an option grant) and not an open-market purchase or sale. Such grants are commonly used to align director incentives with shareholders but do not necessarily signal immediate bullish buying activity. The option will only vest if Conaway continues his board service through the specified vesting date.